Doig CL, et al Knockdown of AKR1C3 exposes a potential epigenetic susceptibility in prostate cancer cells. J Steroid Biochem Mol Biol. 2015 Sep 30;155(Pt A):47-55. doi: 10.1016/j.jsbmb.2015.09.037
Koczula KMa, et al. Metabolic plasticity in CLL: Adaptation to the hypoxic niche. Leukemia. 2015 Jul 23. doi: 10.1038/leu.2015.187
Southam AD, et al. Drug Redeployment to Kill Leukemia and Lymphoma Cells by Disrupting SCD1-Mediated Synthesis of Monounsaturated Fatty Acids. Cancer Res. 2015 Jun 15;75(12):2530-40
Lilly AJ, et al. The case for extracellular Nm23-H1 as a driver of acute myeloid leukaemia (AML) progression. Naunyn Schmiedebergs Arch Pharmacol. 2014 Aug 15.
Khanim F, et al. Selective AKR1C3 inhibitors do not recapitulate the anti-leukaemic activities of the pan-AKR1C inhibitor medroxyprogesterone acetate. Br J Cancer. 2014 Mar 18;110(6):1506-16. doi: 10.1038/bjc.2014.83. Epub 2014 Feb 25.
Molyneux E, et al. Bezafibrate and medroxyprogesterone acetate in resistant and relapsed endemic Burkitt lymphoma in Malawi; an open-label, single-arm, phase 2 study (ISRCTN34303497). Br J Haematol. 2014 Mar;164(6):888-90. doi: 10.1111/bjh.12681..
Lodi A, et al. Proton NMR-based metabolite analyses of archived serial paired serum and urine samples from myeloma patients at different stages of disease activity identifies acetylcarnitine as a novel marker of active disease. PLoS One. 2013;8(2):e56422. doi: 10.1371/journal.pone.0056422.
Khanim FL, et al. Redeployment-based drug screening identifies the anti-helminthic niclosamide as anti-myeloma therapy that also reduces free light chain production.. Blood Cancer Journal 2011 Blood Cancer J. 2011 1(10):e39.
Lilly AJ, et al. Nm23-h1 indirectly promotes the survival of acute myeloid leukemia blast cells by binding to more mature components of the leukemic clone. Cancer Res. 2011 Feb 1;71(3):1177-86. doi: 10.1158/0008-5472
Lodi A, et al. Hypoxia triggers major metabolic changes in AML cells without altering indomethacin-induced TCA cycle deregulation. ACS Chem Biol. 2011 Feb 18;6(2):169-75.
Wright KT, et al. Extracellular Nm23H1 stimulates neurite outgrowth from dorsal root ganglia neurons in vitro independently of nerve growth factor supplementation or its nucleoside diphosphate kinase activity. Biochem Biophys Res Commun. 2010 Jul 16;398(1):79-85. doi: 10.1016/j.bbrc.2010.06.039. Epub 2010 Jun 15.
Veliça P, et al. Prostaglandin D2 inhibits C2C12 myogenesis. Mol Cell Endocrinol. 2010 May 5;319(1-2):71-8. PMID: 20109525
Murray JA, et al. Combined bezafibrate and medroxyprogesterone acetate have efficacy without haematological toxicity in elderly and relapsed acute myeloid leukaemia (AML). Br J Haematol. 2010 Apr;149(1):65-9.
Khanim FL, et al. Combined bezafibrate and medroxyprogesterone acetate: potential novel therapy for acute myeloid leukaemia. PLoS One. 2009 Dec 7;4(12):e8147.
Pearce C, et al. Analysis of the role of COP9 Signalosome (CSN) subunits in K562; the first link between CSN and autophagy. BMC Cell Biol. 2009 Apr 28;10:31.
Birtwistle J, et al. The aldo-keto reductase AKR1C3 contributes to 7,12-dimethylbenz(a)anthracene-3,4-dihydrodiol mediated oxidative DNA damage in myeloid cells: implications for leukemogenesis. Mutat Res. 2009 Mar 9;662(1-2):67-74.
Tiziani S, et al. Metabolomic profiling of drug responses in acute myeloid leukaemia cell lines. PLoS One. 2009;4(1):e4251. Epub 2009 Jan 22. Erratum in: PLoS One. 2009;4(4). doi: 10.1371/annotation/39584d38-04f5-4b37-bfd8-eae2318ec6f9.
Khanim FL, et al. Elevated FOSB-expression; a potential marker of valproate sensitivity in AML. Br J Haematol. 2009 Feb;144(3):332-41.
Hayden RE, et al. Treatment of primary CLL cells with bezafibrate and medroxyprogesterone acetate induces apoptosis and represses the pro-proliferative signal of CD40-ligand, in part through increased 15dDelta12,14,PGJ2. Leukemia. 2009 Feb;23(2):292-304.